A Cholesterol Number You Are Born With
Most people know their LDL, the so-called bad cholesterol. Far fewer know their lipoprotein(a), usually written Lp(a) and pronounced “L-P-little-a.” It is a close cousin of LDL with an extra protein attached, and it is one of the most stubborn risk factors in cardiology. The defining fact is that your Lp(a) level is set largely by your genes, not by what you eat.
That genetic lock is the entire reason Lp(a) sits at the center of Porter Stansberry’s Ignition Point thesis. For the biggest cholesterol problem the public knows about, there are drugs that work. For Lp(a), there have not been. That gap is what the gene-silencing companies are trying to close.
What Lp(a) Actually Is
An Lp(a) particle is an LDL-like particle with an extra protein, called apolipoprotein(a), latched onto it. The gene that codes for that extra protein is the LPA gene, and small differences in that gene explain most of the variation in Lp(a) levels from person to person. Two people can eat the same diet and exercise the same amount, and one will still carry dramatically more Lp(a) than the other.
The particle is pro-inflammatory and promotes clotting, which is why elevated Lp(a) is treated as an independent risk factor for heart attack and stroke. It is not a proxy for ordinary LDL. It is its own problem, and it does not respond to the usual fixes.
Why Diet and Statins Miss It
Here is the frustrating part for patients. Diet and exercise move ordinary LDL cholesterol meaningfully. Statins move it a lot. But Lp(a) barely budges in response to either. Some statins even nudge Lp(a) slightly upward. The level you have is, for practical purposes, the level you are stuck with for life under current medicine.
That is why the medical community has treated elevated Lp(a) as an unmet need for decades. Doctors can measure it, warn patients about it, and then offer very little to actually change it. A drug that could meaningfully lower it would be a genuine first, which is precisely the kind of opening a biotech pitch is built around.
The Gene-Silencing Angle
Because Lp(a) is driven by a gene, it is a natural target for gene silencing. The logic runs straight through the mechanism we explain in our gene silencing explainer: shut down the messenger RNA that produces the LPA protein, and the Lp(a) particle cannot assemble. No diet, no statin, no lifestyle change can do that. Only a drug that interferes with the gene’s instructions can.
Several drugmakers are now racing to be first. We map the four front-running candidates in our Lp(a) drug race guide, and we walk through the harder question of whether lowering the biomarker actually prevents heart attacks in our endpoint problem explainer.
Who Should Care About Their Number
Because Lp(a) is set by genetics, a single test tells you most of what you need to know for life. The level does not swing much with diet, exercise, or weight loss, so there is no point in testing it every year the way people track ordinary cholesterol. One measurement, taken once, is enough to tell a patient whether they carry an elevated level.
That is what makes Lp(a) both a screening success story and a treatment frustration. The test is cheap, widely available, and increasingly ordered alongside a standard lipid panel. What is missing is the other half of the equation: a treatment that reliably lowers the number. Until one of the gene-silencing candidates proves itself, a high Lp(a) result mostly tells a patient to be aggressive about every other risk factor, because the one risk factor they cannot change is the Lp(a) itself. That gap between easy diagnosis and empty treatment is the commercial opening the Ignition Point pitch is built on.
That is a hard message for patients to hear, because it runs against everything they have been told about cholesterol. Eating well and exercising still matter for ordinary LDL and for overall health, but they will not fix a number that was set before birth. The gap between the advice that works for LDL and the advice that does nothing for Lp(a) is precisely why a pharmaceutical answer became so valuable.
The Bottom Line
Lp(a) is a real, genetically determined cardiovascular risk factor that current medicine cannot meaningfully lower. That combination of a large population, a clear genetic cause, and a total absence of good treatment is what makes it such an attractive target for the gene-silencing drug class. The science is sound. The remaining question is not whether Lp(a) can be lowered, but whether lowering it saves lives, and that is a question only large clinical trials can answer.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.